Pharma News

Keep updating your pharma knowledge
18 Feb 2017

New Indication Approval: Boehringer Ingelheim’s asthma drug, Spiriva Respimat

Boehringer Ingelheim has announced that the US Food and Drug Administration (FDA) approved tiotropium Respimat (marketed as Spiriva Respimat) for the long-term, once-daily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenance therapy – usually either inhaled corticosteroid (ICS) alone, or a combination of inhaled corticosteroids/long-acting beta agonists (ICS/LABA).

This approval reflects the comprehensive tiotropium Respimat paediatric clinical trial programme, involving 905 children aged 6-11 years, conducted by Boehringer Ingelheim.

Previously, in September 2015, tiotropium Respimat was approved in the US for the long-term, once-daily, prescription maintenance treatment of asthma in people aged 12 and older. Tiotropium Respimat was approved in the EU in 2014 as an add-on therapy for adults (aged 18 and older) with asthma.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.

Upskill Your Pharma Knowledge

Explore Next Gen Learning

Case Studies & Caselets | Simulation Based Learning | E-Lectures | Online Self Competency Assessments

Thank You for Subscription!